Pfizer Inc. to Post FY2022 Earnings of $6.25 Per Share, Cantor Fitzgerald Forecasts (NYSE:PFE)

Pfizer Inc. (NYSE:PFE – Get Rating) – Cantor Fitzgerald dropped their FY2022 EPS estimates for shares of Pfizer in a report released on Wednesday, May 4th. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings of $6.25 per share for the year, down from their prior forecast of $6.36.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.80 by ($0.18). The firm had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a return on equity of 39.33% and a net margin of 26.97%. The company’s revenue was up 76.8% compared to the same quarter last year. During the same period last year, the business posted $0.93 EPS.

Other analysts also recently issued reports about the company. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. Citigroup upped their price objective on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research report on Tuesday, April 5th. Berenberg Bank set a $50.00 price objective on Pfizer in a report on Thursday, April 21st. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating and set a $52.00 target price for the company. in a research report on Tuesday, February 15th. Finally, Morgan Stanley started coverage on Pfizer in a research report on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $57.05.

PFE stock opened at $48.20 on Friday. The company’s fifty day moving average price is $51.03 and its 200-day moving average price is $51.57. Pfizer has a one year low of $37.96 and a one year high of $61.71. The company has a market capitalization of $272.22 billion, a PE ratio of 11.11, a price-to-earnings-growth ratio of 0.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.19 and a current ratio of 1.40.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ibex Wealth Advisors bought a new position in shares of Pfizer during the 3rd quarter worth about $26,000. Econ Financial Services Corp acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. PYA Waltman Capital LLC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. Rinkey Investments acquired a new stake in Pfizer in the 4th quarter valued at about $32,000. Finally, Stuart Chaussee & Associates Inc. increased its position in Pfizer by 108.3% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 325 shares in the last quarter. Institutional investors own 66.50% of the company’s stock.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Friday, May 13th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.32%. Pfizer’s dividend payout ratio (DPR) is 36.70%.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.